President-elect Donald Trump is reviving the persuasive art of "jawboning" as he uses the bully pulpit to strong-arm straying manufacturers. But for how long will it be effective, and is it in the long-term best interest of the economy?
Pharma giant Novo Nordisk announced Thursday that it is cutting 1,000 jobs after slashing forecasts for 2016, citing lower prices for diabetes drugs. Novo and competitors such as Indianapolis-based Eli Lilly will likely have to keep tightening their belts as prices and profit margins fall, experts say.
The case for Mike Pence as running mate for Donald Trump is he'd bring credibility with evangelical Christians and Republican-elected officials across the ideological spectrum, constituencies with whom Trump's reputation is shaky.